Skip to main content
Premium Trial:

Request an Annual Quote

Owlstone Medical Raises $27M in Series E Round

NEW YORK — Owlstone Medical, a UK-based developer of breath-based diagnostics, said Wednesday that it has closed a $27 million Series E financing round.

The round was led by Ventura Capital and included Aviva Ventures, Horizons Ventures, and the Gates Foundation, which committed $6.5 million to Owlstone in early 2024. Certain undisclosed existing investors also participated.

Owlstone said it will use the new funds to continue developing its core Breath Biopsy technology, which analyzes biomarkers contained in volatile organic compounds and respiratory droplets in exhaled breath. The money will also be used to develop and commercialize diagnostic tests and point-of-care devices based on the technology, the firm said.

In October, Owlstone said that it has been working on tests using parallel approaches to detect in breath endogenous biomarkers of disease and measuring signals produced as the body metabolizes specially prepared solutions. Two of its most advanced products are its Libra test for the early detection of liver disease and its Evolution test for lung cancer.